ALVO OAKTREE ACQUISITION CORP II

Granting of Stock Options and Vesting of Restricted Share Units

Granting of Stock Options and Vesting of Restricted Share Units

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.

The aim of the stock option grants is to align the long-term interests of the board members and the Company. The relevant key terms and conditions of the Company´s Equity Incentive Plan approved by Alvotech’s Annual and Extraordinary General Meeting on June 13, 2022 are as follows:

  • The stock option agreements entitle the grantee to purchase Alvotech shares at an exercise price of USD 9.28 per share*.
  • The options are subject to a vesting period over three years with yearly vesting, i.e. one third of the options vest each year starting on the AGM where the stock options were awarded.  
  • The options are only exercisable if the grantee is still a member of the board of Alvotech at the time of vesting.

Attached to this announcement are filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) made by the respective four independent board directors of their vested RSUs, in accordance with previous grants.

*The exercise price is determined by the opening price of the Company's ordinary shares on the Nasdaq US stock exchange on the date of the grant, in this case on June 25, 2025. 



Alvotech Investor Relations

Benedikt Stefansson, VP

Attachments



EN
01/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

Granting of Stock Options and Vesting of Restricted Share Units

Granting of Stock Options and Vesting of Restricted Share Units In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares. The aim of the stock option grants is to align the long-term interests of the board members and the Company. The relevant key terms and conditions of the Company´s Equity Incentive Plan approved by Alvotech’s Annua...

 PRESS RELEASE

Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda

Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda Í samræmi við starfskjarastefnu sem samþykkt var á aðalfundi Alvotech þann 6. júní 2023 og þar sem nýtt starfsár stjórnar hefst með aðalfundi, voru á aðalfundi félagsins sem haldinn var 25. júní sl. veittir kaupréttir til fjögurra óháðra stjórnarmanna. Hver stjórnarmaður fékk rétt til kaupa á alls 24.784 hlutum í Alvotech. Kaupréttarsamningunum er ætlað að samtvinna hagsmuni stjórnarmanna og Alvotech til lengri tíma. Skilmálar samninganna eru í samræmi við kaupréttarkerfi félagsins sem staðfest var á aðalfundi 13. júní 2022...

 PRESS RELEASE

Alvotech and Advanz Pharma Enter into European Supply and Commercializ...

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commer...

 PRESS RELEASE

Advanz Pharma semur við Alvotech um markaðssetningu í Evrópu á hliðstæ...

Advanz Pharma semur við Alvotech um markaðssetningu í Evrópu á hliðstæðu við líftæknilyfið Cimzia REYKJAVÍK og LONDON, BRETLANDI (1. júlí 2025) - Alvotech (NASDAQ: ALVO) og Advanz Pharma tilkynntu í dag að félögin hafi gert með sér samning um markaðssetningu AVT10 í Evrópu. AVT10 er hliðstæða við líftæknilyfið Cimzia (certolizumab pegol) sem þróun stendur yfir á hjá Alvotech. Alþjóðlega lyfjafyrirtækið Advanz Pharma er með höfuðstöðvar í Bretlandi og markaðssetur lyfseðilsskyld lyf, stungu- og innrennslislyf og lyf við sjaldgæfum sjúkdómum. „Við erum eina fyrirtækið sem vinnur að þróun hli...

 PRESS RELEASE

Alvotech and Advanz Pharma ingår europeiskt leverans- och kommersialis...

Alvotech and Advanz Pharma ingår europeiskt leverans- och kommersialiseringsavtal för biosimilarkandidat till Cimzia® (certolizumab pegol) REYKJAVIK, ISLAND och LONDON, UK (1 juli 2025) — Alvotech (NASDAQ: ALVO), ett globalt biofarmaceutiskt företag som specialiserar sig på utveckling och tillverkning av biosimilära läkemedel för patienter över hela världen, och Advanz Pharma Holdco Limited (“Advanz Pharma”), ett globalt läkemedelsföretag med huvudkontor i Storbritannien och ett strategiskt fokus på specialläkemedel, sjukhusläkemedel och läkemedel för sällsynta sjukdomar i Europa, meddelade...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch